UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis"

Journal of clinical rheumatology, 2024-03, Vol.30 (2), p.e73-e73

2024

Volltextzugriff (PDF)

42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB204-AB204

2023

Volltextzugriff (PDF)

42281 Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB72-AB72

2023

Volltextzugriff (PDF)

42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB85-AB85

2023

Volltextzugriff (PDF)

42297 Insights into the eﬃcacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB57-AB57

2023

Volltextzugriff (PDF)

42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB216-AB216

2023

Volltextzugriff (PDF)

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis

Journal of clinical rheumatology, 2023-08, Vol.29 (5), p.223-229

2023

Volltextzugriff (PDF)

CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Value in health, 2023-06, Vol.26 (6), p.S57-S57

2023

Volltextzugriff (PDF)

PCR185 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis

Value in health, 2023-06, Vol.26 (6), p.S346-S347

2023

Volltextzugriff (PDF)

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology, 2022-10, Vol.36 (10), p.1774-1783

2022

Volltextzugriff (PDF)

33129 Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB199-AB199

2022

Volltextzugriff (PDF)

33133 A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB132-AB132

2022

Volltextzugriff (PDF)

EE291 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study Interim Analysis of Tildrakizumab in Patients with Moderate to Severe Psoriasis

Value in health, 2022-07, Vol.25 (7), p.S390-S391

2022

Volltextzugriff (PDF)

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

The Journal of dermatological treatment, 2022-01, Vol.33 (1), p.219-228

2022

Volltextzugriff (PDF)

25983 Rates of individual and composite cardiovascular events through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB78-AB78

2021

Volltextzugriff (PDF)

25993 Efficacy of long-term tildrakizumab for plaque psoriasis: PASI 50/75/90/100 and PGA for up to 5 years of treatment in reSURFACE 2

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB80-AB80

2021

Volltextzugriff (PDF)

25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB78-AB78

2021

Volltextzugriff (PDF)

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Annals of the rheumatic diseases, 2021-09, Vol.80 (9), p.1147-1157

2021

Volltextzugriff (PDF)

25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB80-AB80

2021

Volltextzugriff (PDF)

25984 Gastrointestinal adverse events related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB78-AB78

2021

Volltextzugriff (PDF)

25992 Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB79-AB79

2021

Volltextzugriff (PDF)

25357 Malignancies related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB56-AB56

2021

Volltextzugriff (PDF)

25363 Serious infections and infections related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB56-AB56

2021

Volltextzugriff (PDF)

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1

Journal of the European Academy of Dermatology and Venereology, 2021-08, Vol.35 (8), p.e526-e528

2021

Volltextzugriff (PDF)

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

British journal of dermatology (1951), 2021-08, Vol.185 (2), p.323-334

2021

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(110)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(44)
Animals
(29)
Mice
(28)
Immunology
(20)
Humans
(18)
Female
(17)
Dermatology
(15)
Mice, Inbred C57bl
(13)
Mice, Inbred Nzb
(13)
Biological And Medical Sciences
(12)
Male
(12)
Mice, Inbred Balb C
(11)
Crosses, Genetic
(10)
Lupus Erythematosus, Systemic - Genetics
(10)
Genetic Predisposition To Disease
(9)
Psoriasis - Drug Therapy
(9)
Autoantibodies - Biosynthesis
(8)
Lupus Erythematosus, Systemic - Immunology
(8)
Lupus Nephritis - Genetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Response to: "Interleukin-23 Blockade Is Not Effective in Axial Spondyloarthritis"

42290 Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis

42281 Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

42295 Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis

42297 Insights into the eﬃcacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials

42293 Real-world effectiveness of tildrakizumab in a Phase 4 study in patients with moderate-to- severe plaque psoriasis

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis

CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

PCR185 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

33129 Real-world effectiveness and safety of tildrakizumab in patients with moderate to severe plaque psoriasis: Week 28 interim analysis of a phase 4 study

33133 A phase 4, real-world study of tildrakizumab in moderate to severe psoriasis: Week 28 interim analysis

EE291 Psoriasis-Related Work Productivity Improvement from a Phase 4 Real-World Study Interim Analysis of Tildrakizumab in Patients with Moderate to Severe Psoriasis

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials

25983 Rates of individual and composite cardiovascular events through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

25993 Efficacy of long-term tildrakizumab for plaque psoriasis: PASI 50/75/90/100 and PGA for up to 5 years of treatment in reSURFACE 2

25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52

Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1

25984 Gastrointestinal adverse events related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

25992 Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment

25357 Malignancies related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

25363 Serious infections and infections related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)

Suchergebnisse filtern